Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
Lily Dasso, Tala Al-Khaled, Sriram Sonty, et al.
Clinical ophthalmology (2018) Vol. Volume 12, pp. 1939-1944
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Nikki A. Mehran, Sapna Sinha, Reza Razeghinejad
Eye (2019) Vol. 34, Iss. 1, pp. 72-88
Open Access | Times Cited: 77
Design, Synthesis, and Evaluation of Piperazine‐7‐Deazapurine Based Thiazolidone Derivatives as Novel ROCK Inhibitors
Sandeep Kumar Thoota, Suresh Maddila, Sai Kiran S. S. Pindiprolu, et al.
ChemistrySelect (2025) Vol. 10, Iss. 3
Closed Access | Times Cited: 1
A tissue-engineered human trabecular meshwork hydrogel for advanced glaucoma disease modeling
Haiyan Li, Tyler Bagué, Alexander Kirschner, et al.
Experimental Eye Research (2021) Vol. 205, pp. 108472-108472
Open Access | Times Cited: 44
Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy
Jun Wang, Hanke Wang, Yalong Dang
Ophthalmology and Therapy (2023) Vol. 12, Iss. 6, pp. 2943-2957
Open Access | Times Cited: 13
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
Mansi Batra, Sumeet Gupta, Anroop B. Nair, et al.
European Journal of Ophthalmology (2021) Vol. 31, Iss. 5, pp. 2237-2244
Closed Access | Times Cited: 28
Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease
Faraat Ali, Anam Ilyas
Current Research in Translational Medicine (2022) Vol. 70, Iss. 3, pp. 103343-103343
Closed Access | Times Cited: 19
Emerging targets in drug discovery against neurodegenerative diseases: Control of synapsis disfunction by the RhoA/ROCK pathway
Olmo Martín-Cámara, Ángel Cores, Pilar López‐Alvarado, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113742-113742
Closed Access | Times Cited: 26
Systemic side effects of glaucoma medications
Amirmohsen Arbabi, Xuan Bao, Wesam Shamseldin Shalaby, et al.
Clinical and Experimental Optometry (2021) Vol. 105, Iss. 2, pp. 157-165
Closed Access | Times Cited: 24
Unmet needs in glaucoma therapy: The potential role of hydrogen sulfide and its delivery strategies
Susmit Mhatre, Catherine A. Opere, Somnath Singh
Journal of Controlled Release (2022) Vol. 347, pp. 256-269
Closed Access | Times Cited: 16
Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: A pilot investigation in sturge-weber syndrome
Aaron R. Kaufman, Abdelrahman M. Elhusseiny, Deepak P. Edward, et al.
European Journal of Ophthalmology (2023) Vol. 33, Iss. 5, pp. 1969-1976
Closed Access | Times Cited: 9
Crystalline keratopathy following long-term netarsudil therapy
Olivia W. Cummings, Jesús M. Meléndez-Montañez, Leah Naraine, et al.
American Journal of Ophthalmology Case Reports (2024) Vol. 35, pp. 102069-102069
Open Access | Times Cited: 3
Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
C. Ellis Wisely, Huan Sheng, Theresa Heah, et al.
Advances in Therapy (2020) Vol. 37, Iss. 3, pp. 1114-1123
Open Access | Times Cited: 21
A Case Report Illustrating the Postoperative Course of Descemetorhexis without Endothelial Keratoplasty with Topical Netarsudil Therapy
Pimpiroon Ploysangam, Sangita P. Patel
Case Reports in Ophthalmological Medicine (2019) Vol. 2019, pp. 1-7
Open Access | Times Cited: 22
Recent advances in the development of cyclin-dependent kinase 7 inhibitors
Yuou Teng, Kui Lu, Qian Zhang, et al.
European Journal of Medicinal Chemistry (2019) Vol. 183, pp. 111641-111641
Closed Access | Times Cited: 20
Two pediatric cases of reticular corneal epithelial edema associated with netarsudil
Maria A. Guzman Aparicio, Daniel L. Liebman, James Chodosh, et al.
American Journal of Ophthalmology Case Reports (2022) Vol. 27, pp. 101638-101638
Open Access | Times Cited: 10
Rho-Proteins and Downstream Pathways as Potential Targets in Sepsis and Septic Shock: What Have We Learned from Basic Research
Maria Luísa da Silveira Hahmeyer, José Eduardo da Silva‐Santos
Cells (2021) Vol. 10, Iss. 8, pp. 1844-1844
Open Access | Times Cited: 14
Reticular Bullous Epithelial Corneal Edema after Netarsudil Use for Elevated Intraocular Pressure with Concurrent Fuchs Endothelial Corneal Dystrophy: A Case Report
Kathryn S. Park, Alexander Lieu, Michael J. Ang, et al.
Case Reports in Ophthalmology (2024) Vol. 15, Iss. 1, pp. 369-373
Open Access | Times Cited: 1
Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials
Jo‐Hsuan Wu, Sheng‐Nan Chang, Takashi Nishida, et al.
Graefe s Archive for Clinical and Experimental Ophthalmology (2021) Vol. 260, Iss. 3, pp. 937-948
Closed Access | Times Cited: 10
Response to netarsudil in goniotomy-treated eyes and goniotomy-naïve eyes: a pilot study
Haochen Xu, Marwa T. Thomas, Dayeong Lee, et al.
Graefe s Archive for Clinical and Experimental Ophthalmology (2022) Vol. 260, Iss. 9, pp. 3001-3007
Closed Access | Times Cited: 5
Fixed-combination topical anti-hypertensive ophthalmic agents
Lindsay Machen, Reza Razeghinejad, Jonathan S. Myers
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 10, pp. 1269-1282
Closed Access | Times Cited: 7
Effects of Netarsudil on the Corneal Endothelium
Thomas K. Mundorf, Francis S. Mah, Huan Sheng, et al.
Ophthalmology Glaucoma (2020) Vol. 3, Iss. 6, pp. 421-425
Open Access | Times Cited: 6
Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect
Sandy Samuel, Hani El Helwe, Cameron Neeson, et al.
Journal of Ophthalmology (2022) Vol. 2022, pp. 1-15
Open Access | Times Cited: 4
Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Ahmad A. Aref, Lawrence S. Geyman, Abdel-Rahman Zakieh, et al.
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 12, pp. 1073-1079
Closed Access | Times Cited: 4
Rho-Kinase-Hemmer als neue lokale Therapieoption beim primären Offenwinkelglaukom
Carl Erb, K. Konieczka
Der Ophthalmologe (2021) Vol. 118, Iss. 5, pp. 449-460
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top